Can intravenous fosfomycin be used to treat a kidney infection in a patient with a history of kidney stones?

Intravenous Fosfomycin for Kidney Infection in Patients with Kidney Stone History

Intravenous fosfomycin can be used to treat pyelonephritis in patients with a history of kidney stones, but oral fosfomycin should be avoided because it lacks strong efficacy data for upper urinary tract infections. 1, 2

Key Distinction: IV vs. Oral Formulation

• Oral fosfomycin tromethamine is FDA-approved only for uncomplicated cystitis in women and is explicitly not indicated for pyelonephritis or perinephric abscess. 2
• Intravenous fosfomycin achieves extensive tissue distribution including renal parenchyma and has demonstrated efficacy in complicated urinary tract infections and pyelonephritis in multiple real-world studies. 3, 4, 5, 6
• The 2024 JAMA guidelines acknowledge that IV fosfomycin may be reasonable empirical treatment for pyelonephritis in countries where it is available, though they note a lack of strong randomized trial data. 1

Specific Considerations for Kidney Stone History

• Patients with recurrent kidney stones do not require treatment of asymptomatic bacteriuria unless they are undergoing a mucosa-breaching urological procedure. 7
• If the patient has symptomatic pyelonephritis (fever, flank pain, systemic symptoms), this is a complicated UTI requiring treatment regardless of stone history. 7
• Persistent colonization with urease-producing organisms (e.g., Proteus mirabilis) warrants imaging to exclude struvite stones, as these convert asymptomatic bacteriuria into a complicated infection requiring both antimicrobial therapy and possible urological intervention. 7

Dosing and Administration of IV Fosfomycin

• Standard dosing for pyelonephritis is 4–8 grams every 8 hours (12–24 g/day), with most real-world studies using 16 g/day divided into three doses. 8
• Treatment duration should be 7 days when adequate source control (e.g., stone removal, obstruction relief) has been achieved, consistent with guideline recommendations for gram-negative bacteremia from a urinary source. 1, 9
• IV fosfomycin is almost always used in combination with other agents (99% of cases in real-world data), most commonly with piperacillin/tazobactam, carbapenems, or new beta-lactam/beta-lactamase inhibitor combinations. 5, 8
• Fosfomycin achieves excellent renal tissue penetration and concentrates in urine, making it particularly suitable for upper urinary tract infections. 2, 6

Clinical Algorithm for Decision-Making

Step 1 – Confirm Symptomatic Infection:

• Fever, flank pain, costovertebral angle tenderness, or systemic symptoms indicate pyelonephritis requiring treatment. 7
• Asymptomatic bacteriuria with stone history alone does not require treatment. 7

Step 2 – Assess for Complicated Features:

• Obtain imaging (ultrasound or CT) if persistent urease-producing organism (Proteus, Klebsiella) is present to exclude obstructing stones. 7
• Obstruction or abscess converts this to a complicated UTI requiring both antimicrobials and urological intervention. 7

Step 3 – Select IV Fosfomycin Regimen:

• Use 8 grams three times daily (24 g/day) for multidrug-resistant organisms or when MIC is 64–128 mg/L. 10
• Use 4–6 grams three times daily (12–18 g/day) for susceptible organisms with MIC ≤32 mg/L. 10, 8
• Always combine with another agent (e.g., ceftriaxone, piperacillin/tazobactam, or carbapenem) based on local resistance patterns and culture results. 5, 8

Step 4 – Monitor for Adverse Events:

• Electrolyte disturbances occur in 23.7% of patients, with hypernatremia being most common. 11
• Check serum sodium, potassium, calcium, and magnesium at baseline and every 2–3 days during therapy. 12, 11
• Patients with pre-existing kidney dysfunction are at higher risk for electrolyte imbalances and require more frequent monitoring. 12

Step 5 – Duration and Follow-Up:

• Treat for 7 days total if source control is achieved and clinical improvement occurs within 72 hours. 1, 9
• If fever persists beyond 72 hours, obtain repeat imaging to exclude abscess or obstruction. 9

Common Pitfalls to Avoid

• Do not use oral fosfomycin for pyelonephritis—it lacks FDA approval and guideline support for upper tract infections. 1, 2
• Do not use IV fosfomycin as monotherapy except in rare cases of uncomplicated UTI; combination therapy is standard practice in 99% of real-world cases. 5, 8
• Do not overlook electrolyte monitoring—hypernatremia and hypokalemia are common and can lead to therapy discontinuation in 17% of patients. 11
• Do not assume all kidney stone patients need treatment—only symptomatic infections or pre-procedural prophylaxis warrant antibiotics. 7
• Do not forget to image for stones if the organism is a urease-producer (Proteus, Klebsiella), as undetected struvite stones convert colonization into a complicated infection requiring surgical management. 7

Safety Profile

• IV fosfomycin has an excellent safety profile even with prolonged use (weeks), including in critically ill patients. 6
• Adverse events are generally mild to moderate and include electrolyte disturbances (hypernatremia 23.7%, hypokalemia, hypocalcemia, hypomagnesemia) and gastrointestinal symptoms (2.9%). 12, 5, 11
• Therapy discontinuation due to adverse events occurs in 17% of patients, primarily due to electrolyte imbalances. 11
• Therapeutic drug monitoring (TDM) may predict adverse events, with trough levels >200 mg/L in intermittent infusion showing 91% AUROC for predicting hypernatremia. 11